Free Trial
NASDAQ:PTCT

PTC Therapeutics Q2 2025 Earnings Report

PTC Therapeutics logo
$52.13 +0.02 (+0.04%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$51.61 -0.52 (-1.01%)
As of 08/1/2025 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTC Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$1.07
Beat/Miss
N/A
One Year Ago EPS
N/A

PTC Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$173.01 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

PTC Therapeutics Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

PTC Therapeutics Earnings Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
Equities Analysts Offer Predictions for PTCT FY2025 Earnings
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $46.00
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $84.00
See More PTC Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PTC Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PTC Therapeutics and other key companies, straight to your email.

About PTC Therapeutics

PTC Therapeutics (NASDAQ:PTCT), a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

View PTC Therapeutics Profile

More Earnings Resources from MarketBeat